225Ac-J591 for Prostate Cancer

"The study necessitates that those seeking to participate are aged between 18 and 99. Additionally, there exist 76 trials for minors and 1350 studies catered specifically toward the elderly population."

"This clinical trial is recruiting participants, with the initial posting dated June 30th 2021 and latest update on August 23rd 2022. Perusal of clinicaltrials.gov provides this information."

"177Lu-PSMA-I&T is commonly employed to combat tumor antigens, as well as potentially diagnose suspected metastasis, positron emission tomography (PET) scans and prostate cancer."

"Affirmative. The clinicaltrials.gov database indicates that this study is presently seeking participants, with the original posting having occurred on June 30th 2021 and updated August 23rd 2022. This trial requires 33 patients from 2 sites to be enrolled."

"Currently, there are 41 active clinical trials researching 177Lu-PSMA-I&T with 4 of the initiatives in Phase 3. Of these studies, several are based out of Melbourne, Victoria; however, a total of 252 medical centres globally have been tapped to host research for this drug."

"This trial is seeking 33 participants with prostate cancer aged between 18-99. To be eligible, applicants must meet a series of stringent criteria including: having an absolute neutrophil count >2,000 cells/mm3; hemoglobin ≥9 g/dL; platelet count >150,000 x 109/uL and serum creatinine <1.5xULN or calculated creatinine clearance ≥60 mL/min/1.73 m2 by Cockcroft-Gault; histologically or cytologically confirmed adenocarcinoma of the prostate as well as documented progressive metastatic CRPC based on Pro"

"The primary purpose of this investigation over a period of 100 months is to measure the dose-limiting toxic effects caused by 225Ac-J591 and 177Lu-PSMA-I&T during dose escalation. Secondary objectives include monitoring biochemical progression, assessing treatment safety based on NCI CTCAE version 5.0 guidelines, and measuring overall survival rate."